Following up on an eventful 2016, this year brings plenty of value-creating events for marijuana stocks. Here’s what to look for with Insys Therapeutics (NASDAQ:INSY), GW Pharmaceuticals (NASDAQ:GWPH) and Corbus Pharmaceuticals Holdings (NASDAQ:CRBP).
Last July, Insys Therapeutics gained approval from the Food and Drug Administration for Syndros, its pharmaceutical version of tetrahydrocannabinol (THC) — a component of marijuana — that treats anorexia associated with weight loss in AIDS patients and cancer-induced nausea and vomiting. But the company can’t sell the drug yet, because it still needs to wait for the Drug Enforcement Agency to schedule it.
The different levels of scheduling — from Schedule 1 to Schedule 5 — are based on the likelihood that the drug will be abused; they determine how regulated pharmacies and doctors are in distributing the drug. Schedule